Senores Pharmaceuticals Limited (BOM:544319)
India · Delayed Price · Currency is INR 1,042.95
-5.85 (-0.56%)
At close: Jun 4, 2026
Senores Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 6,326 | 3,983 | 2,145 | 353.37 | 141.7 | |
Revenue Growth (YoY) | 58.85% | 85.65% | 507.07% | 149.38% | - |
Cost of Revenue | 2,517 | 1,874 | 1,089 | 127.96 | 80.75 |
Gross Profit | 3,810 | 2,108 | 1,057 | 225.41 | 60.95 |
Selling, General & Admin | 1,123 | 636 | 363.1 | 51.75 | 28.92 |
Other Operating Expenses | 1,004 | 575.1 | 277.5 | 46.93 | 12.51 |
Operating Expenses | 2,439 | 1,380 | 740.8 | 116.47 | 48.48 |
Operating Income | 1,371 | 728.8 | 315.8 | 108.94 | 12.47 |
Interest Expense | -250.3 | -203.7 | -85 | -18.37 | -5.1 |
Interest & Investment Income | - | 71.6 | 4.6 | 0.39 | 1.93 |
Currency Exchange Gain (Loss) | - | 34 | 10.7 | 34.21 | 2.68 |
Other Non Operating Income (Expenses) | 480.7 | 75.2 | 3.6 | -0.77 | -0.55 |
EBT Excluding Unusual Items | 1,601 | 705.9 | 249.7 | 124.4 | 11.43 |
Gain (Loss) on Sale of Assets | - | -0.2 | -0.3 | -0.03 | - |
Pretax Income | 1,601 | 705.7 | 249.4 | 124.37 | 11.43 |
Income Tax Expense | 375.7 | 122.3 | -77.6 | 40.04 | 1.52 |
Earnings From Continuing Operations | 1,225 | 583.4 | 327 | 84.33 | 9.91 |
Minority Interest in Earnings | -61.6 | 2.2 | -12.5 | - | - |
Net Income | 1,164 | 585.6 | 314.5 | 84.33 | 9.91 |
Net Income to Common | 1,164 | 585.6 | 314.5 | 84.33 | 9.91 |
Net Income Growth | 98.74% | 86.20% | 272.94% | 750.96% | - |
Shares Outstanding (Basic) | 44 | 36 | 23 | 10 | 5 |
Shares Outstanding (Diluted) | 44 | 36 | 26 | 13 | 5 |
Shares Change (YoY) | 21.26% | 41.13% | 103.16% | 131.33% | - |
EPS (Basic) | 26.39 | 16.10 | 13.67 | 8.87 | 1.81 |
EPS (Diluted) | 26.39 | 16.10 | 12.21 | 6.65 | 1.81 |
EPS Growth | 63.89% | 31.88% | 83.61% | 267.92% | - |
Free Cash Flow | -2,027 | -2,034 | -775.3 | -483.56 | -211.29 |
Free Cash Flow Per Share | -45.96 | -55.94 | -30.09 | -38.12 | -38.53 |
Gross Margin | 60.22% | 52.94% | 49.25% | 63.79% | 43.01% |
Operating Margin | 21.67% | 18.30% | 14.72% | 30.83% | 8.80% |
Profit Margin | 18.40% | 14.70% | 14.66% | 23.86% | 6.99% |
Free Cash Flow Margin | -32.04% | -51.08% | -36.14% | -136.84% | -149.11% |
EBITDA | 1,683 | 882.4 | 404.8 | 109.55 | 12.61 |
EBITDA Margin | 26.61% | 22.16% | 18.87% | 31.00% | 8.90% |
D&A For EBITDA | 312.5 | 153.6 | 89 | 0.61 | 0.14 |
EBIT | 1,371 | 728.8 | 315.8 | 108.94 | 12.47 |
EBIT Margin | 21.67% | 18.30% | 14.72% | 30.83% | 8.80% |
Effective Tax Rate | 23.46% | 17.33% | - | 32.19% | 13.30% |
Revenue as Reported | 6,797 | 4,175 | 2,173 | 390.21 | 146.31 |
Advertising Expenses | - | 32.3 | 8.5 | 3.82 | 0.31 |